The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Siddhesh Anant Nayak & PACs
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mr. Siddhesh Anant Nayak, part of the promoter group, along with persons acting in concert (PACs), acquired 2,400 equity shares (0.11%) of Clinitech Laboratory Ltd on March 24, 2026. Post-acquisition, the promoter group's total holding increased from 14,60,600 shares (63.99%) to 14,63,000 shares (64.10%) of the company. The total equity share capital of the company remains unchanged at 22,82,400 shares. This is a routine creeping acquisition disclosure under SEBI's Takeover Regulations, and no special category of securities (warrants, encumbrance, etc.) was involved.
This is a very small acquisition that slightly increases the promoter group's already dominant stake, signaling continued promoter confidence in the company. It is unlikely to have any material impact on the stock price since the change in holding is negligible.